which have protective effects on cardiovascular homeostasis. There are 4 types of EETs, 5, 6-, 8, 9-, 11, 12-, and 14, 15-EET, among which 14, 15-EET is of high concentration in vasculature and have the closest relationship with CVD. 12 In patients with established coronary heart disease, increasing serum EET levels was associated with lower risk of CVD. 13, 14 The polymorphism of the soluble sEH (epoxide hydrolase) gene was a significant predictor of coronary artery calcification status even after adjusting for traditional risk factors. 15 Accumulating preclinical and epidemiological evidence suggest that inhibition of sEH-mediated EET hydrolysis has various cardiovascular protective effects including anti-inflammation. 16, 17 Because EETs are easily hydrolyzed and hard to detect directly, the levels of their metabolite, dihydroxyeicosatrienoic acids (DHETs), are commonly used to reflect EET levels, which are also reported to be closely associated with CVD. 18, 19 Therefore, in our study, we assessed 14, 15-DHET as an indirect measure of 14, 15-EET levels.
Preclinical studies showed that the aldosterone infusion in rats increased sEH protein expression in renal cortex and microvasculature. Aldosterone treatment of endothelial cells also significantly increased mRNA expression of sEH. 20 In deoxycorticosterone acetate-salt-treated mice, a model that mimics hyperaldosteronism, we demonstrated that the level of 20-hydroxyeicosatetraenoic acid was significantly reduced and further contributed to increased sodium retention and blood pressure. 21 This phenomenon indicated that excess aldosterone secretion inhibited the production of EETs. However, whether downregulation of 14, 15-EET is associated with vascular damage in patients with PA is unknown. Thus, we conducted a case-control clinical study to measure serum 14, 15-DHET and investigated its role in AAC in patients with PA.
Methods
The authors declare that all supporting data are available within the article.
Study Population
This was a single-center, case-controlled study conducted in Sun Yat-sen Memorial Hospital of Sun Yat-sen University. From January 2013 to June 2015, a total of 117 patients suspicious of PA who were admitted to our unit, 20 patients who did not meet the following inclusion criteria or met the exclusion criteria were excluded. And we also excluded 28 patients missing the data of computerized tomography (CT) or serum biomedical tests. Baseline clinical and biochemical data were extracted from the hospital database.
PA cases and essential hypertension (EH) controls were included in the study when meeting the diagnostic criteria as detailed below. Patients with clinical or laboratory evidence of associated conditions were excluded from this study, such as: (1) administration of any antihypertensive drugs within 2 weeks before recruitment; (2) recent infection inflammatory disorders or hormonal replacement therapies; and (3) history of chronic kidney diseases, hepatic diseases, rheumatologic diseases, or malignancy including adrenocortical carcinoma.
This study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki by the Ethics Committee of Sun Yat-sen University, and written informed consent was obtained from every study participants.
Our screening methods and diagnostic criteria for PA and EH were in accordance with the current guideline. 22 After the withdrawal of medication influencing the renin-aldosterone system, patients were screened for PA using plasma aldosterone concentration (PAC) to PRA (aldosterone-to-renin ratio, ng/L per ng/mL per hour), with a cutoff of 25 ng/L per ng/mL per hour in the standing position. Diagnosis of PA was confirmed by the failure of aldosterone suppression after the oral sodium-loading test (24-hour urinary aldosterone concentration ≥10 μg/24 h) and captopril test (PAC ≥130 ng/L) as previously described. 22, 23 During the same period, patients with EH were included when meeting the following criteria: a known history of hypertension with antihypertensive drugs treatment; and 3 documented office systolic blood pressure ≥140 mm Hg and diastolic blood pressure ≥90 mm Hg at different days; secondary forms of hypertension were excluded by reviewing records for medical history, physical examination, and appropriate biochemical tests and imaging studies. Notably, only patients who had a normal aldosterone-to-renin ratio were included as EH controls. In the present study, patients with PA and EH controls were 1:1 individually matched for age (±3 years), sex, and blood pressure (±5 mm Hg) were included as controls.
Multidetector CT Analysis of Abdominal Aorta
All patients underwent an adrenal CT scan to evaluate abdominal aortic plaques. The plaques occupied by calcified tissue >50% of the plaque area (an area ≥1 mm 2 with density of >130 HU) were classified as calcified plaques. 24 All imaging procedures were done on the same equipment using the same parameters. To measure AAC, the CT images were reconstructed in a 35-cm field of view with a slice thickness of 1 mm. All the scans were read by the Siemens Syngo CT Workplace at the same radiological department in our unit, and calcification in the distal abdominal aorta above the aortic bifurcation was used for analysis. AAC Agatston score was calculated by multiplying each calcified plaque area volumes by weighted scores assigned to the highest density of calcification (1 for 130-199 HU; 2 for 200-299 HU; 3 for 300-399 HU; 4 for 400 HU; and greater) within the individual calcified plaque area. According to the AAC score, patients were grouped as having no detectable AAC (Agatston score=0), mild (1-100), and severe (>100) AAC as previously described. 25 All the abdominal arterial data sets were analyzed by 2 blinded and experienced investigators.
14, 15-DHET Measurements
Peripheral venous blood samples were collected from each recruited patient at 7:00 am before patients had the breakfast. After repeating the procedures of acidification, extraction, and saponification for 3 times, we pooled all the organic phase (ethyl acetate) together and evaporated under argon gas. Then, we dissolved the dried residue of each sample in a minimal amount of ethanol (≈20 µL). An ELISA was used to measure the serum 14, 15-DHET (14, 15-DHET ELISA kit; Detroit R&D, Inc, Detroit, MI) according to the manual. 26 
Laboratory Testing
Blood samples were drawn between 08:00 am and 11:00 am after at least 2-hour upright posture, usually after they had been seated for 5 to 15 minutes. Aldosterone in plasma and urine were measured by radioimmunoassay using a commercial kit Diagnostic Products (DSL, TX). The intra-and interassay coefficients of variation for PAC were 4.5% and 9.8%, respectively, and the reference range was 38.1 to 313.3 ng/L. PRA as the generation of angiotensin I in vitro was determined as previously described. The intra-and interassay coefficients of variation for PRA were 5.6% and 10%, respectively, and the reference range was (2.63±1.32) ng/mL per hour. Biochemical parameters, potassium, calcium (Ca), phosphorus (Pi), creatinine, alkaline phosphatase, fasting plasma glucose, HbA1c (glycated hemoglobin), triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, Hs-CRP (high-sensitivity C-reactive protein), and urinary albumin excretion rate were analyzed using a standardized and certified TBA-120 auto-analyzer (Toshiba Medical Systems, Japan) in the institutional central laboratory. Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation with modified coefficients for the Chinese population.
Statistical Analysis
Continuous variables with a normal distribution were reported as mean (±SD); skewed data as median (interquartile range). Categorical variables were presented as numbers (percentages). Baseline variables between patients with PA and matched EH were compared using paired Student t test, Wilcoxon sign test, or McNemar test according to the types of variables. Correlation analysis and linear regression analysis was used to explore the factors affecting serum 14, 15-DHET levels and AAC severity in PA patients. Univariate and multivariate logistic analysis were used to investigate the association between serum 14, 15-DHET, and AAC scores, as well as in further subgroup analysis. Data were expressed as the odds ratio (OR) and 95% confidence interval (CI). Subgroup analysis was divided according to the cardiovascular risk factors affecting AAC. 28 Data were analyzed with SPSS version 20 (SPSS, Inc, Chicago, IL), and 2-sided P values <0.05 were considered statistically significant.
Results

Baseline Characteristics of the Study Population
The clinical and biochemical characteristics of 69 patients with PA and 69 EH controls are shown in Table 1 . Patients with PA had higher PAC and aldosterone to renin ratio and lower PRA and serum potassium than matched EH patients (all P<0.05). Patients with PA showed lower body mass index (BMI), accompanied by lower serum levels of lowdensity lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride (all P<0.05). In contrast, urinary albumin excretion rate and urinary aldosterone were significantly higher in PA patients than that in controls (both P<0.05). However, no significant difference was found in the other biochemical parameters (serum Ca, Pi, total cholesterol, creatinine, alkaline phosphatase, Hs-CRP, fasting plasma glucose, HbA1c, and estimated glomerular filtration rate) between these 2 groups. Of interest, patients with PA had a higher prevalence of abdominal aortic calcified plaques than matched EH controls (27 [ 
Risk Factors of Serum 14, 15-DHET in PA Patients
As shown in Figure 1 , serum 14, 15-DHET levels were significantly higher in patients with PA than matched EH controls (7.18±4.98 versus 3.50±2.07 ng/mL; P<0.001). Notably, PA characteristic factors, including serum potassium or PRA, showed no significant relationship with serum 14, 15-DHET (Figures S1 and S2 in the online-only Data Supplement). To explore whether LnPAC was an independent risk factor influencing 14, 15-DHET in PA, multiple linear regression analysis was used. We found that LnPAC was an independent risk factor of increased serum 14, 15-DHET after adjustment for age, BMI, systolic blood pressure, diastolic blood pressure, and serum lipid profiles (β=0.444; P<0.001; Table 2 ).
Association Between Serum 14, 15-DHET and AAC Scores in Patients With PA
To evaluate the relationship between serum 14, 15-DHET and AAC scores in patients with PA, we measured serum levels of 14, 15-DHET in PA patients with different levels of AAC. As shown in Figure 2A , serum 14, 15-DHET levels progressively Values are shown as mean±SD or median (25th-75th quartiles) for continuous variables and n (%) for categorical variables. AAC indicates abdominal aortic calcification; ALP, alkaline phosphatase; ARR, aldosterone-renin ratio; BMI, body mass index; Ca, calcium; CPs, calcified plaques; DBP, diastolic blood pressure; DHP, duration of hypertension; eGFR, estimated glomerular filtration rate; EH, essential hypertension; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; Hs-CRP, high-sensitivity C-reactive protein; LDL-C, lowdensity lipoprotein cholesterol; PA, primary aldosteronism; PAC, plasma aldosterone concentration; Pi, phosphate; PRA, plasma renin activity; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; and UAER, urinary albumin excretion rate.
increased as the severity of AAC increased (median 5.01 versus 6.37 versus 15.09 ng/mL, in no AAC, mild AAC, and severe AAC groups, respectively; P<0.001). Moreover, serum 14, 15-DHET levels were significantly associated with AAC scores in patients with PA (r=0.593; P<0.001; Figure 2B ).
Identifying the PA Population With High Risk of AAC
As shown in Table 3 , 14, 15-DHET was significantly associated with increased risk of AAC on univariate analysis (OR, 1.329; 95% CI, 1.153-1.532; P<0.001). This association remained after adjusting for age, systolic blood pressure, Ca, Pi, alkaline phosphatase, low-density lipoprotein cholesterol, Hs-CRP, and estimated glomerular filtration rate (OR, 1.371; 95% CI, 1.145-1.640; P<0.001). To explore the specific PA patients with increased risk of AAC induced by 14, 15-EET alteration, we performed subgroup analysis based on traditional risk factors. As shown in Figure 3 , we found that the positive association between serum 14, 15-DHET and AAC extent was significant in PA patients with <50 years of age (OR, 1.552; 95% CI, 1.116-2.158; P=0.009), mild hypertension (OR, 1.530; 95% CI, 1.158-2.020; P=0.003), and normal BMI (OR, 1.320; 95% CI, 1.063-1.639; P=0.012). However, the association between 14, 15-DHET and AAC in PA was not significant in sex subgroups (both P>0.05).
Discussion
Major findings from our study demonstrate that (1) patients with PA exhibit more frequent and more severe AAC compared with matched EH controls and (2) increased serum 14, 15-DHET, which possibly associates with excess PAC, is an independent risk factor for AAC, especially in PA patients with <50 years with normal BMI and systolic blood pressure <160 mm Hg. Target-organ damage in PA patients is a major cause of cardiovascular complications worldwide. 29 Thus, early diagnosis and appropriate control of risk factors of CVD is critical for PA patients. By comparing PA patients with matched controls, our study revealed that VC might be a novel important risk factor for PA patients beyond blood pressure elevation. As a nontraditional indicator for CVD, VC has been reported to be associated with increased risk of CVD. 6 Accordingly, exploring the possible mechanisms of VC warrants further study. Instead of a passive product of calcium and phosphate precipitation, VC is now thought to be an actively regulated process. 30 Many factors contribute to the development of VC, among which chronic inflammation is a key player. 31, 32 In humans, focal arterial inflammation, as quantified by 18 F-fluorodeoxyglucose/positron emission tomography, was suggested to precede calcification within the same locations. 33 Fish oils, such as eicosapentaenoic acid, inhibited osteoblastic differentiation in vascular smooth muscle cells and VC through anti-inflammatory effects on nuclear factor-κB. 34 In support of this, our study revealed that low anti-inflammatory 14, 15-EET, reflected by high 14, 15-DHET levels, was an independent risk factor of AAC in PA patients. Therefore, suppressing inflammation by increasing EETs may be cardiovascular protective and reduce the risk of VC in PA patients.
Produced and generated from endothelial cells, EETs possess potent vasodilatory and anti-inflammatory effects in maintaining vascular homeostasis. 35 It was reported that some isoforms of EETs (such as 11, 12-EET) except for 14, 15-EET might induce vasoconstriction when cyclooxygenases/ prostaglandins signaling was altered. 36 However, our study patients had no history of taking nonsteroidal drugs, which is known to influence prostaglandins balance. It still warrants further investigation to identify this issue. Clinical studies have demonstrated that increasing EET levels have use as a cardioprotective therapeutic strategy in coronary heart diseases, stroke, diabetes mellitus, etc. [37] [38] [39] Many factors influence EET metabolism, including obesity, age, and serum lipids. In obese individuals with coronary heart disease, increased body mass was significantly associated with low plasma EET levels and 14, 15-EET/14, 15-DHET ratio.
14 Increasing EET levels by sEH inhibitors also had antiatherosclerotic effects, which was associated with low-density lipoprotein cholesterol reduction and high-density lipoprotein cholesterol elevation. 26, 40 But in PA patients, we observed that excess PAC was independently associated with higher serum 14, 15-DHETs after adjustment for these traditional risk factors. In deoxycorticosterone acetate-salt-treated mice, production of 20-hydroxyeicosatetraenoic acid was reduced. 21 Clinical studies revealed that abnormal activation of the renin-angiotensin-aldosterone system might be the main reason for the altered production of EETs by increasing sEH expression. 35 Our study also showed that excess PAC was associated with decreased 14, 15-EET levels in PA patients.
Another interesting result of our study was the association between serum 14, 15-DHET levels and the extent of AAC. This was especially evident in younger PA patients with mild hypertension and normal BMI. These data suggest that in low-risk PA patients, 28 downregulation of 14, 15-EET may trigger AAC formation in the early stage. This may explain why 14, 15-EET showed no effect on AAC in older PA patients with severe hypertension and abnormal nutrition. With a series of traditional cardiovascular risks, patients with PA tended to exhibit advanced and severe AAC, and even increasing EETs could not bring further benefits to its regression. However, further investigation is still required to verify our results.
This study has several limitations that should be highlighted. First, because the prevalence of PA is low in the Chinese population, 41 the number of PA patients enrolled in the study was relatively small. Therefore, further studies with larger sample size are needed to verify our findings. Second, because of the cross-sectional design of the present study, causality between serum 14, 15-DHET levels and AAC extent cannot be established despite adjustment for possible factors. Third, angiotensin II was not measured in our study; angiotensin II can upregulate EET production and thereby complicate interpretation. 42 However, changes in levels of angiotensin II may be inhibited because of overproduced aldosterone in PA, which may be difficult to assess. Further studies are needed to unravel this aspect. Fourth, it was not possible to obtain vascular tissue for direct measurement of sEH activity; thus, we measured 14, 15-DHET to reflect serum 14, 15-EET levels. 26 Finally, high-performance liquid chromatography was a standard method for quantifying cytochrome P450-derived eicosanoid metabolite concentrations. 13 In this study, we used a simpler method, ELISA, to specifically measure serum 14, 15-DHET levels. However, the results from both methods were proven to be comparable. 21 In conclusion, we provide clinical evidence that patients with PA have significantly higher AAC compared with matched EH controls. Downregulation of 14, 15-EET is probably an important predictor of AAC in patients with PA, especially in younger PA patients with mild hypertension and normal BMI.
Perspectives
Our findings suggest that the downregulated serum 14, 15-EET is closely associated with an increase of AAC in patients with PA. Therefore, measuring serum 14, 15-DHET, a surrogate marker of 14, 15-EET, may provide a valuable additional tool for future AAC evaluation in PA. 
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